Company: DMAC
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0001437749-25-026286
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On August 12, 2025, DiaMedica Therapeutics Inc. (the “ Company”) entered into a Sales Agreement (the “ Sales Agreement”) with TD Securities (USA) LLC (“ TD Cowen”), as sales agent, pursuant to which the Company may offer and sell its common shares, no par value per share (the “ Common Shares”), from time to time through TD Cowen. The Company may offer and sell Common Shares for an aggregate offering amount of up to $100.0 million under the Sales Agreement (the “ ATM Shares”).

Upon delivery of an issuance notice and subject to the terms and conditions of the Sales Agreement, sales of the ATM Shares, if any, will be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “ Securities Act”). TD Cowen is not required to sell any specific number or dollar amount of securities but will act as sales agent using commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations on mutually agreed terms between TD Cowen and the Company. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

The Sales Agreement provides that TD Cowen will be entitled to compensation for its services of up to 3.0% of the gross proceeds of the ATM Shares sold under the Sales Agreement. The proceeds the Company receives from sales of the ATM Shares, if any, will depend on the number of ATM Shares actually sold and the offering price of such ATM Shares. The Company has agreed to pay certain of TD Cowen’s costs and expenses incident to the performance of its obligations under the Sales Agreement. The Company has also agreed to provide indemnification and reimbursement to TD Cowen with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended.

The Sales Agreement contains customary representations, warranties, and agreements by the Company and customary indemnification rights and obligations of the parties. The representations, warranties, and agreements contained in the Sales Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties.

This Current Report on Form 8-K shall not constitute an offer to sell or solicitation of an offer to buy the ATM Shares, nor